Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 376 Cr.
- Current Price ₹ 312
- High / Low ₹ 417 / 234
- Stock P/E 121
- Book Value ₹ 30.0
- Dividend Yield 0.00 %
- ROCE 6.48 %
- ROE -4.61 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 10.4 times its book value
- Company has a low return on equity of -5.64% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | 35 | 39 | 46 | 50 | 59 | 59 | 77 | 62 | 80 | 93 | 108 | 112 | |
28 | 31 | 33 | 38 | 43 | 51 | 54 | 69 | 61 | 71 | 91 | 101 | 101 | |
Operating Profit | 3 | 4 | 6 | 8 | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 7 | 10 |
OPM % | 9% | 11% | 15% | 16% | 14% | 14% | 9% | 10% | 1% | 12% | 3% | 6% | 9% |
0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 1 | |
Interest | 1 | 1 | 2 | 2 | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 5 | 3 |
Depreciation | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
Profit before tax | 0 | 2 | 3 | 4 | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | 5 |
Tax % | 412% | 48% | 21% | 33% | 22% | 31% | 19% | 11% | -28% | 15% | -23% | 168% | |
-0 | 1 | 3 | 3 | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | 3 | |
EPS in Rs | -0.58 | 0.70 | 2.24 | 2.56 | 2.90 | 2.66 | 2.31 | 3.69 | -4.59 | 2.24 | -0.85 | -1.27 | 2.07 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 13% |
3 Years: | 20% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 22% |
TTM: | 190% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 47% |
3 Years: | 64% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -6% |
3 Years: | -6% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 |
Reserves | -22 | -21 | -19 | -17 | -4 | -3 | -7 | -3 | -7 | -4 | -5 | 20 | 24 |
64 | 66 | 70 | 69 | 56 | 75 | 62 | 64 | 77 | 70 | 72 | 68 | 64 | |
10 | 11 | 11 | 11 | 17 | 20 | 27 | 31 | 34 | 34 | 37 | 41 | 39 | |
Total Liabilities | 63 | 66 | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 139 |
34 | 35 | 33 | 34 | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 46 | 51 | |
CWIP | 0 | 0 | 0 | 0 | 6 | 11 | 12 | 14 | 14 | 4 | 7 | 7 | 9 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
29 | 32 | 40 | 39 | 41 | 59 | 47 | 56 | 68 | 62 | 61 | 88 | 79 | |
Total Assets | 63 | 66 | 73 | 73 | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 139 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-8 | -0 | 0 | 6 | 4 | -10 | 12 | 5 | 7 | -0 | 10 | 2 | |
-4 | -1 | -0 | -3 | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -1 | |
11 | 1 | 2 | -2 | 0 | 17 | -12 | 1 | 6 | -13 | -1 | 18 | |
Net Cash Flow | -0 | -1 | 2 | -0 | 1 | 4 | -2 | 2 | 12 | -16 | 2 | 18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47 | 36 | 35 | 33 | 35 | 34 | 43 | 51 | 61 | 61 | 51 | 53 |
Inventory Days | 223 | 413 | 287 | 227 | 319 | 338 | 311 | 313 | 268 | 254 | 227 | 258 |
Days Payable | 160 | 245 | 150 | 100 | 112 | 125 | 117 | 162 | 149 | 168 | 137 | 129 |
Cash Conversion Cycle | 110 | 204 | 172 | 160 | 242 | 247 | 236 | 202 | 179 | 147 | 141 | 182 |
Working Capital Days | -0 | 5 | 19 | 26 | 49 | 138 | 50 | 37 | 8 | 30 | 5 | 17 |
ROCE % | 2% | 5% | 8% | 9% | 9% | 9% | 6% | 9% | -0% | 11% | 2% | 6% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov
- Financial Results Q2 2024 15 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
15 Nov - KAL reports 23% revenue growth and plans global expansion.
-
Board Meeting Outcome for Outcome Of Board Meeting
14 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Intimation for The Quarter Ended 30Th Sept 2024
11 Nov - Board meeting to approve financial statements for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2018TranscriptNotesPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants